Literature DB >> 18512821

Serum-free transient protein production system based on adenoviral vector and PER.C6 technology: high yield and preserved bioactivity.

M J E Havenga1, L Holterman, I Melis, S Smits, J Kaspers, E Heemskerk, R van der Vlugt, M Koldijk, G J Schouten, G Hateboer, K Brouwer, R Vogels, J Goudsmit.   

Abstract

Stable E1 transformed cells, like PER.C6, are able to grow at scale and to high cell densities. E1-deleted adenoviruses replicate to high titer in PER.C6 cells whereas subsequent deletion of E2A from the vector results in absence of replication in PER.C6 cells and drastically lowers the expression of adenovirus proteins in such cells. We therefore considered the use of an DeltaE1/DeltaE2 type 5 vector (Ad5) to deliver genes to PER.C6 cells growing in suspension with the aim to achieve high protein yield. To evaluate the utility of this system we constructed DeltaE1/DeltaE2 vector carrying different classes of protein, that is, the gene coding for spike protein derived from the Coronavirus causing severe acute respiratory syndrome (SARS-CoV), a gene coding for the SARS-CoV receptor or the genes coding for an antibody shown to bind and neutralize SARS-CoV (SARS-AB). The DeltaE1/DeltaE2A-vector backbones were rescued on a PER.C6 cell line engineered to constitutively over express the Ad5 E2A protein. Exposure of PER.C6 cells to low amounts (30 vp/cell) of DeltaE1/DeltaE2 vectors resulted in highly efficient (>80%) transduction of PER.C6 cells growing in suspension. The efficient cell transduction resulted in high protein yield (up to 60 picogram/cell/day) in a 4 day batch production protocol. FACS and ELISA assays demonstrated the biological activity of the transiently produced proteins. We therefore conclude that DeltaE1/DeltaE2 vectors in combination with the PER.C6 technology may provide a viable answer to the increasing demand for high quality, high yield recombinant protein.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18512821      PMCID: PMC7161845          DOI: 10.1002/bit.21757

Source DB:  PubMed          Journal:  Biotechnol Bioeng        ISSN: 0006-3592            Impact factor:   4.530


  61 in total

Review 1.  Recombinant protein expression for therapeutic applications.

Authors:  Dana C Andersen; Lynne Krummen
Journal:  Curr Opin Biotechnol       Date:  2002-04       Impact factor: 9.740

Review 2.  Glycoproteins from insect cells: sialylated or not?

Authors:  I Marchal; D L Jarvis; R Cacan; A Verbert
Journal:  Biol Chem       Date:  2001-02       Impact factor: 3.915

3.  Cloning, expression, and crystallization of the fusion protein of Newcastle disease virus.

Authors:  L Chen; P M Colman; L J Cosgrove; M C Lawrence; L J Lawrence; P A Tulloch; J J Gorman
Journal:  Virology       Date:  2001-11-25       Impact factor: 3.616

Review 4.  Inducible gene expression systems for higher eukaryotic cells.

Authors:  M Gossen; A L Bonin; S Freundlieb; H Bujard
Journal:  Curr Opin Biotechnol       Date:  1994-10       Impact factor: 9.740

5.  Thermolabile DNA binding proteins from cells infected with a temperature-sensitive mutant of adenovrius defective in viral DNA synthesis.

Authors:  P C Van Der Vliet; A J Levine; M J Ensinger; H S Ginsberg
Journal:  J Virol       Date:  1975-02       Impact factor: 5.103

6.  In vitro and in vivo biology of recombinant adenovirus vectors with E1, E1/E2A, or E1/E4 deleted.

Authors:  M Lusky; M Christ; K Rittner; A Dieterle; D Dreyer; B Mourot; H Schultz; F Stoeckel; A Pavirani; M Mehtali
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

7.  Trans-complementation of E1-deleted adenovirus: a new vector to reduce the possibility of codissemination of wild-type and recombinant adenoviruses.

Authors:  J L Imler; A Bout; D Dreyer; A Dieterlé; H Schultz; D Valerio; M Mehtali; A Pavirani
Journal:  Hum Gene Ther       Date:  1995-06       Impact factor: 5.695

8.  Introduction, stable integration, and controlled expression of a chimeric adenovirus gene whose product is toxic to the recipient human cell.

Authors:  D F Klessig; D E Brough; V Cleghon
Journal:  Mol Cell Biol       Date:  1984-07       Impact factor: 4.272

9.  Recombinant human preproinsulin. Expression, purification and reaction with insulin autoantibodies in sera from patients with insulin-dependent diabetes mellitus.

Authors:  H Berg; M Walter; L Mauch; J Seissler; W Northemann
Journal:  J Immunol Methods       Date:  1993-09-15       Impact factor: 2.303

10.  Monoclonal antibodies which recognize native and denatured forms of the adenovirus DNA-binding protein.

Authors:  N C Reich; P Sarnow; E Duprey; A J Levine
Journal:  Virology       Date:  1983-07-30       Impact factor: 3.616

View more
  12 in total

1.  Adenoviral vector DNA for accurate genome editing with engineered nucleases.

Authors:  Maarten Holkers; Ignazio Maggio; Sara F D Henriques; Josephine M Janssen; Toni Cathomen; Manuel A F V Gonçalves
Journal:  Nat Methods       Date:  2014-08-24       Impact factor: 28.547

2.  Differential integrity of TALE nuclease genes following adenoviral and lentiviral vector gene transfer into human cells.

Authors:  Maarten Holkers; Ignazio Maggio; Jin Liu; Josephine M Janssen; Francesca Miselli; Claudio Mussolino; Alessandra Recchia; Toni Cathomen; Manuel A F V Gonçalves
Journal:  Nucleic Acids Res       Date:  2012-12-28       Impact factor: 16.971

Review 3.  Adenoviral vector-based strategies against infectious disease and cancer.

Authors:  Chao Zhang; Dongming Zhou
Journal:  Hum Vaccin Immunother       Date:  2016-04-22       Impact factor: 3.452

4.  Adenoviral vectors encoding CRISPR/Cas9 multiplexes rescue dystrophin synthesis in unselected populations of DMD muscle cells.

Authors:  Ignazio Maggio; Jin Liu; Josephine M Janssen; Xiaoyu Chen; Manuel A F V Gonçalves
Journal:  Sci Rep       Date:  2016-11-15       Impact factor: 4.379

5.  Polyethyleneimine-based transient gene expression processes for suspension-adapted HEK-293E and CHO-DG44 cells.

Authors:  David L Hacker; Divor Kiseljak; Yashas Rajendra; Sarah Thurnheer; Lucia Baldi; Florian M Wurm
Journal:  Protein Expr Purif       Date:  2013-09-08       Impact factor: 1.650

6.  High-Capacity Adenoviral Vectors Permit Robust and Versatile Testing of DMD Gene Repair Tools and Strategies in Human Cells.

Authors:  Marcella Brescia; Josephine M Janssen; Jin Liu; Manuel A F V Gonçalves
Journal:  Cells       Date:  2020-04-02       Impact factor: 6.600

7.  Adenoviral vector delivery of RNA-guided CRISPR/Cas9 nuclease complexes induces targeted mutagenesis in a diverse array of human cells.

Authors:  Ignazio Maggio; Maarten Holkers; Jin Liu; Josephine M Janssen; Xiaoyu Chen; Manuel A F V Gonçalves
Journal:  Sci Rep       Date:  2014-05-29       Impact factor: 4.379

8.  Selection-free gene repair after adenoviral vector transduction of designer nucleases: rescue of dystrophin synthesis in DMD muscle cell populations.

Authors:  Ignazio Maggio; Luca Stefanucci; Josephine M Janssen; Jin Liu; Xiaoyu Chen; Vincent Mouly; Manuel A F V Gonçalves
Journal:  Nucleic Acids Res       Date:  2016-01-13       Impact factor: 16.971

Review 9.  Human cell lines for biopharmaceutical manufacturing: history, status, and future perspectives.

Authors:  Jennifer Dumont; Don Euwart; Baisong Mei; Scott Estes; Rashmi Kshirsagar
Journal:  Crit Rev Biotechnol       Date:  2015-09-18       Impact factor: 8.429

Review 10.  Adenoviral Vectors Meet Gene Editing: A Rising Partnership for the Genomic Engineering of Human Stem Cells and Their Progeny.

Authors:  Francesca Tasca; Qian Wang; Manuel A F V Gonçalves
Journal:  Cells       Date:  2020-04-13       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.